

Precision SGLT2 Inhibitor Strategies for Cardiovascular and Renal Outcomes in Type 2 Diabetes

Waiswa Arajab

Department of Pharmacy Kampala International University Uganda

Email: arajab.waiswa@studwc.kiu.ac.ug

ABSTRACT

Cardiovascular and renal complications remained the leading causes of morbidity and mortality in type 2 diabetes, affecting approximately 537 million adults globally in 2021 with projections exceeding 783 million by 2045. Sodium-glucose cotransporter-2 (SGLT2) inhibitors transformed diabetes management by demonstrating robust cardiorenal protection beyond glycaemic control, yet optimal implementation strategies require precision approaches tailored to individual risk profiles. This narrative review synthesized current evidence on precision strategies for SGLT2 inhibitor use to optimize cardiovascular and renal outcomes in type 2 diabetes, evaluating patient selection, risk stratification, and implementation considerations. A systematic search of peer-reviewed literature, cardiovascular outcome trials, and guideline documents published from 2015 to 2026 informed this narrative synthesis. Meta-analytic data from 13 randomized trials encompassing 92,920 patients demonstrated that SGLT2 inhibitors reduce cardiovascular mortality by 12 percent, heart failure hospitalization by 29 percent, and renal composite endpoints by 35 percent. Benefits were consistent across baseline blood pressure, kidney function, and cardiovascular risk strata, with greatest absolute risk reductions in high-risk populations. SGLT2 inhibitors represented a cornerstone of precision diabetes care, offering substantial cardiorenal protection when strategically deployed according to individual risk profiles. Their integration into clinical practice requires early initiation, appropriate patient selection, and sustained therapy to maximize long-term benefits.

Keywords: SGLT2 inhibitors, Type 2 diabetes, Cardiovascular outcomes, Renal protection, Precision medicine.

INTRODUCTION

Type 2 diabetes constitutes a global health crisis of unprecedented magnitude, with an estimated 537 million adults affected worldwide in 2021, a figure projected to escalate to 783 million by 2045 [1, 2]. Cardiovascular and renal complications account for most of the diabetes-related morbidity and mortality, with cardiovascular diseases responsible for approximately 17.9 million deaths annually and diabetes-related kidney disease contributing to 2.0 million deaths. Individuals with type 2 diabetes face a two- to four-fold increased risk of cardiovascular events compared to those without diabetes, while chronic kidney disease affects approximately 40 percent of the diabetic population, dramatically amplifying the risk of progression to end-stage renal disease and cardiovascular death [3]. The therapeutic landscape for type 2 diabetes has undergone a paradigm shift with the advent of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of agents that extend benefits far beyond glycaemic control [4, 5]. Initially developed as glucose-lowering medications, SGLT2 inhibitors have demonstrated remarkable cardiorenal protective effects in large-scale cardiovascular outcome trials, fundamentally altering treatment guidelines and clinical practice. Landmark trials including EMPA-REG OUTCOME, DECLARE-TIMI 58, CREDENCE, and DAPA-CKD have consistently shown reductions in major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, and progression of kidney disease. A 2025 meta-analysis of 13 randomized trials involving 92,920 patients confirmed that SGLT2 inhibitors reduce cardiovascular mortality by 12 percent, heart failure hospitalization by 29 percent, and renal composite endpoints by 35 percent compared with placebo [6]. Despite this robust evidence base, significant heterogeneity exists in clinical implementation, with

many eligible patients not receiving these life-prolonging therapies. Precision medicine approaches that tailor SGLT2 inhibitor selection and timing to individual patient characteristics, risk profiles, and comorbidities are essential to optimize outcomes and resource allocation. This narrative review addresses this critical need by synthesizing current evidence on precision strategies for SGLT2 inhibitor use in type 2 diabetes [3].

The article is organized into five sections. First, we describe the mechanisms of action and pleiotropic effects underlying cardiorenal protection. Second, we present efficacy data from cardiovascular outcome trials and meta-analyses, stratified by patient subgroups and risk categories. Third, we evaluate safety profiles and contraindications relevant to precision prescribing. Fourth, we discuss clinical implementation strategies, including early initiation, risk stratification algorithms, and integration with other therapies. Fifth, we highlight evidence gaps and future research directions. The purpose of this review is to provide clinicians and researchers with a comprehensive, evidence-based framework for implementing precision SGLT2 inhibitor strategies that maximize cardiovascular and renal benefits in type 2 diabetes. By consolidating available data and contextualizing findings within current guidelines, this review aims to support individualized, risk-stratified treatment decisions that improve patient outcomes.

Mechanisms of Action and Pleiotropic Effects Underlying Cardiorenal Protection

SGLT2 inhibitors exert their therapeutic effects through inhibition of sodium-glucose cotransporter-2 proteins expressed predominantly in the proximal renal tubules, responsible for reabsorbing approximately 90 percent of filtered glucose [7]. By blocking this transporter, SGLT2 inhibitors induce glucosuria and osmotic diuresis, lowering blood glucose independently of insulin secretion and reducing body weight through caloric loss. However, their cardiorenal benefits extend well beyond glycaemic control, mediated through multiple pleiotropic mechanisms that favorably modify cardiovascular and renal pathophysiology [6]. Hemodynamic effects constitute a central mechanism of cardiorenal protection. SGLT2 inhibitors promote natriuresis and osmotic diuresis, reducing intravascular volume and preload, which lowers blood pressure and cardiac filling pressures [8]. Systolic blood pressure reductions of 3 to 5 mmHg are consistently observed across trials, contributing to reduced afterload and myocardial oxygen demand [9, 10]. Importantly, these agents restore tubuloglomerular feedback by increasing sodium delivery to the macula densa, inducing afferent arteriolar vasoconstriction and reducing intraglomerular pressure. This hemodynamic effect mitigates glomerular hyperfiltration, a key driver of diabetic kidney disease progression, and explains the early, reversible decline in estimated glomerular filtration rate observed after initiation [6]. Metabolic and anti-inflammatory effects further contribute to cardiorenal benefits. SGLT2 inhibitors reduce circulating uric acid levels, improve insulin sensitivity, and shift substrate utilization toward ketone bodies, which may enhance myocardial efficiency [11, 12]. A 2025 meta-analysis demonstrated significant reductions in inflammatory biomarkers, including interleukin-6 and tumor necrosis factor- α , suggesting attenuation of chronic low-grade inflammation implicated in atherosclerosis and kidney fibrosis. Weight loss of 2 to 3 kilograms on average reduces visceral adiposity, improves lipid profiles, and decreases mechanical stress on the cardiovascular system [6]. Direct cardiac and vascular effects have also been proposed, including improvements in myocardial energetics, reduction of cardiac fibrosis, and enhancement of endothelial function. While flow-mediated dilation data remain inconsistent, experimental studies suggest SGLT2 inhibitors may reduce oxidative stress and improve nitric oxide bioavailability in the vasculature. These multifaceted mechanisms collectively explain the consistent cardiorenal benefits observed across diverse patient populations, irrespective of baseline glycaemic control or blood pressure [6].

Efficacy Evidence from Cardiovascular Outcome Trials and Meta-Analyses

Robust evidence from randomized controlled trials and meta-analyses establishes the efficacy of SGLT2 inhibitors in reducing cardiovascular and renal outcomes across diverse patient subgroups [13]. A 2025 systematic review and meta-analysis of 13 trials encompassing 92,920 patients demonstrated that SGLT2 inhibitors significantly reduce all-cause mortality (risk ratio 0.89), cardiovascular mortality (risk ratio 0.88), heart failure hospitalization (risk ratio 0.71), and renal composite endpoints (risk ratio 0.65) compared with placebo. These benefits were consistent across eight different SGLT2 inhibitors, including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, supporting a class effect [6]. Individual cardiovascular outcome trials provide granular insights into specific populations. The EMPA-REG OUTCOME trial, involving 7,020 patients with type 2 diabetes and established cardiovascular disease, demonstrated a 38 percent relative risk reduction in cardiovascular death with empagliflozin [14]. The DECLARE-TIMI 58 trial, enrolling 17,160 patients with or without cardiovascular disease, showed a 17 percent reduction in heart failure hospitalization with dapagliflozin. The CREDENCE trial, focused on 4,401 patients with diabetic kidney disease, reported a 30 percent reduction in renal composite endpoints with canagliflozin. These trials collectively affirm that SGLT2 inhibitors confer benefits across the spectrum of cardiovascular and renal risk [6]. Precision analyses reveal that benefits are preserved across baseline characteristics. A 2024 meta-analysis of nine cardiovascular outcome trials involving 68,600 patients examined outcomes stratified by baseline blood pressure and found no significant interaction between blood pressure category and treatment effect. Patients with normal baseline blood pressure (systolic less than 140 mmHg)

experienced hazard ratios of 0.88 for major adverse cardiovascular events and 0.55 for composite renal outcomes, while those with elevated blood pressure had hazard ratios of 0.88 and 0.61, respectively. Similarly, benefits are consistent across baseline kidney function, with significant risk reductions observed even in patients with estimated glomerular filtration rates below 30 mL/min/1.73 m² [3]. Absolute risk reductions vary according to baseline risk, supporting precision approaches that prioritize high-risk populations. Patients with established cardiovascular disease, chronic kidney disease, or multiple risk factors derive the greatest absolute benefits, with number-needed-to-treat estimates ranging from 20 to 50 over 3 to 5 years for major outcomes [15]. Conversely, lower-risk patients may experience smaller absolute benefits, though relative risk reductions remain comparable. These data underscore the importance of risk stratification in optimizing SGLT2 inhibitor deployment [3].

Safety Profiles and Contraindications Relevant to Precision Prescribing

The safety and tolerability of SGLT2 inhibitors are generally favorable, with specific adverse event profiles that inform precision prescribing decisions. Genital mycotic infections represent the most common adverse effect, occurring in 4 to 6 percent of patients compared to 1 to 2 percent with placebo, reflecting increased glucosuria [16]. These infections are typically mild to moderate, responsive to antifungal therapy, and rarely lead to treatment discontinuation. Volume depletion-related events, including hypotension and dehydration, occur in 3 to 5 percent of patients, particularly in those on diuretics or with reduced kidney function, necessitating careful monitoring and dose adjustment of concomitant diuretics [3]. Diabetic ketoacidosis, though rare, represents a serious adverse event requiring vigilance. The risk is approximately 2.6-fold higher with SGLT2 inhibitors compared to placebo, with an absolute incidence of 0.2 to 0.3 percent in cardiovascular outcome trials [17, 18]. Predisposing factors include insulin deficiency, acute illness, reduced caloric intake, and excessive alcohol consumption. Patient education on recognizing symptoms and temporarily discontinuing therapy during acute illness or surgical procedures is essential to mitigate this risk [3]. Lower limb amputations were initially reported with canagliflozin in the CANVAS trial, though subsequent trials and meta-analyses have not confirmed a class-wide signal. A 2025 meta-analysis found no significant increase in amputation risk across SGLT2 inhibitors (risk ratio 1.06). Fracture risk similarly shows no consistent association, with pooled analyses demonstrating neutral effects [6]. Contraindications include type 1 diabetes, diabetic ketoacidosis, severe renal impairment (estimated glomerular filtration rate below 20 to 25 mL/min/1.73 m² for most agents), and pregnancy. Caution is advised in patients with recurrent genital infections, volume depletion, or those at high risk for ketoacidosis. These safety considerations inform precision prescribing by identifying patients who may require enhanced monitoring, dose modifications, or alternative therapies [3].

Clinical Implementation Strategies for Precision SGLT2 Inhibitor Use

Integrating SGLT2 inhibitors into diabetes care requires strategic, precision-based approaches that align with individual patient characteristics, risk profiles, and treatment goals. Current guidelines from the American Diabetes Association and European Society of Cardiology recommend SGLT2 inhibitors as first-line therapy in patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, irrespective of glycaemic control or metformin use. For patients without these comorbidities but with multiple cardiovascular risk factors, SGLT2 inhibitors should be considered early in the treatment algorithm to maximize long-term benefits [3]. Risk stratification algorithms facilitate precision prescribing by identifying patients most likely to benefit. High-priority candidates include those with established atherosclerotic cardiovascular disease, heart failure with reduced or preserved ejection fraction, albuminuric chronic kidney disease, or combinations thereof. Intermediate-priority patients include those with long-standing diabetes, multiple risk factors (hypertension, dyslipidemia, smoking, obesity), or early markers of kidney disease. Lower-priority patients, such as those with recent-onset diabetes and no comorbidities, may still benefit but derive smaller absolute risk reductions [3]. Early initiation is critical to maximizing cardiorenal protection. Post-hoc analyses suggest that benefits accrue rapidly, with risk reductions for heart failure hospitalization observed within weeks of initiation. Delaying SGLT2 inhibitor therapy until later disease stages may forfeit opportunities to prevent irreversible cardiovascular and renal damage. Clinicians should consider initiating SGLT2 inhibitors at diagnosis in high-risk patients, rather than reserving them as add-on therapy after multiple treatment failures [6]. Dosing and agent selection should account for kidney function, comorbidities, and patient preferences. Empagliflozin and dapagliflozin have the most robust evidence across cardiovascular and renal outcomes, while canagliflozin has strong data for kidney disease. Once-daily dosing improves adherence, and generic availability enhances accessibility. Combining SGLT2 inhibitors with glucagon-like peptide-1 receptor agonists may provide additive benefits in patients with obesity or inadequate glycaemic control, though cost and tolerability must be considered [19]. Multidisciplinary care involving endocrinologists, cardiologists, nephrologists, and primary care providers optimizes implementation. Patient education on mechanisms, benefits, and potential adverse events enhances adherence and self-management. Regular monitoring of kidney function, volume status, and glycaemic control ensures safe, effective therapy. Addressing cost barriers through formulary management and patient assistance programs promotes equitable access [3].

Evidence Gaps and Future Research Directions

Despite substantial evidence supporting SGLT2 inhibitors, critical knowledge gaps persist that limit optimal precision implementation. Most cardiovascular outcome trials enrolled patients with mean ages of 63 to 67 years, leaving uncertainty regarding benefits and safety in older adults with frailty, polypharmacy, and multimorbidity [20]. Real-world effectiveness studies in diverse healthcare settings, including low- and middle-income countries where diabetes burden is highest, are needed to confirm trial findings and identify implementation barriers [6].

Head-to-head comparisons between different SGLT2 inhibitors are lacking, precluding definitive conclusions about relative efficacy and safety. Subgroup analyses by ethnicity, sex, and genetic markers are limited, hindering personalized treatment approaches. The underrepresentation of certain populations, including indigenous groups and those with advanced kidney disease, further limits generalizability [6]. Long-term outcomes beyond 5 years remain uncertain, particularly regarding durability of cardiorenal protection, effects on diabetes remission, and potential for late adverse events. Ongoing trials examining SGLT2 inhibitors in type 1 diabetes, non-diabetic heart failure, and earlier stages of kidney disease will expand the evidence base. Investigation of combination therapies, including dual SGLT1/2 inhibition and triple incretin-SGLT2 regimens, may offer additional benefits [19].

Implementation science research is needed to optimize delivery models, address cost barriers, and ensure equitable access. Biomarker discovery efforts may identify predictors of treatment response, enabling truly personalized therapy. Finally, health economic analyses comparing SGLT2 inhibitors with alternative therapies across diverse healthcare systems will inform resource allocation and policy decisions [6].

CONCLUSION

SGLT2 inhibitors represent a transformative advance in type 2 diabetes management, offering robust cardiovascular and renal protection that extends well beyond glycaemic control. Evidence from 13 randomized trials involving 92,920 patients demonstrates consistent reductions in cardiovascular mortality, heart failure hospitalization, and progression of kidney disease across diverse patient subgroups. These benefits are mediated through multifaceted mechanisms, including hemodynamic, metabolic, anti-inflammatory, and direct organ-protective effects. Precision implementation strategies that prioritize high-risk populations, initiate therapy early, and tailor agent selection to individual characteristics maximize clinical benefits. Current guidelines support SGLT2 inhibitor use as first-line therapy in patients with established cardiovascular disease, heart failure, or chronic kidney disease, with expanding indications for those at elevated risk. Safety profiles are favorable, with genital infections, volume depletion, and rare ketoacidosis as primary concerns requiring vigilance and patient education. Significant evidence gaps remain regarding long-term outcomes, comparative efficacy between agents, and generalizability to underrepresented populations. Future research should prioritize extended follow-up trials, real-world effectiveness studies, and implementation strategies to optimize access and adherence. Clinicians should prioritize early initiation of SGLT2 inhibitors in patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, using risk stratification algorithms to guide precision prescribing and maximize cardiorenal protection.

REFERENCES

1. Krishnamoorthy, R., Gatasheh, M.K., Subbarayan, S., Vijayalakshmi, P., Uti, D.E.: Protective Role of Jimson Weed in Mitigating Dyslipidemia, Cardiovascular, and Renal Dysfunction in Diabetic Rat Models: *In Vivo* and *in Silico* Evidence. *Natural Product Communications*. 19, 1934578X241299279 (2024). <https://doi.org/10.1177/1934578X241299279>
2. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. *Diabetes & Vascular Disease Research*. 22, 14791641251334726 (2025). <https://doi.org/10.1177/14791641251334726>
3. Mavrakanas, T.A., Tsoukas, M.A., Brophy, J.M., Sharma, A., Gariani, K.: SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. *Sci Rep*. 13, 15922 (2023). <https://doi.org/10.1038/s41598-023-42989-z>
4. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.A. (2025). Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. *Obesity Medicine*, 2025; 100622. <https://doi.org/10.1016/j.obmed.2025.100622>.
5. Brown, E., Wilding, J.P.H., Barber, T.M., Alam, U., Cuthbertson, D.J.: Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. *Obesity Reviews*. 20, 816–828 (2019). <https://doi.org/10.1111/obr.12841>
6. Haider, S.H., Irfan, A., Sheikh, S.M., Larik, M.O., Raza, A., Khabir, Y.: Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients. *Clin Med Insights Cardiol*. 19, 11795468251347777 (2025). <https://doi.org/10.1177/11795468251347777>

7. DeFronzo, R.A., Reeves, W.B., Awad, A.S.: Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. *Nat Rev Nephrol.* 17, 319–334 (2021). <https://doi.org/10.1038/s41581-021-00393-8>
8. Kantar, Y.Ç., Açmaz, B., Kantar, A., Kuzu, Z., Şahin, Ö., Günel, A.İ.: Improvement in left ventricular ejection fraction and fluid compartment dynamics in patients with heart failure and type 2 diabetes treated with SGLT-2 inhibitors. *BMC Cardiovasc Disord.* 26, 504 (2026). <https://doi.org/10.1186/s12872-026-05873-y>
9. Abdul-Ghani, M., Del Prato, S., Chilton, R., DeFronzo, R.A.: SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. *Diabetes Care.* 39, 717–725 (2016). <https://doi.org/10.2337/dc16-0041>
10. Hedman, K., Cauwenberghs, N., Christle, J.W., Kuznetsova, T., Haddad, F., Myers, J.: Workload-indexed blood pressure response is superior to peak systolic blood pressure in predicting all-cause mortality. *Eur. J. Prev. Cardiol.* 27, 978–987 (2020). <https://doi.org/10.1177/2047487319877268>
11. Vargas-Delgado, A.P., Arteaga Herrera, E., Tumbaco Mite, C., Delgado Cedeno, P., Van Loon, M.C., Badimon, J.J.: Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. *International Journal of Molecular Sciences.* 24, 4144 (2023). <https://doi.org/10.3390/ijms24044144>
12. Bailey, C.J.: Uric acid and the cardio-renal effects of SGLT2 inhibitors. *Diabetes, Obesity and Metabolism.* 21, 1291–1298 (2019). <https://doi.org/10.1111/dom.13670>
13. McGuire, D.K., Shih, W.J., Cosentino, F., Charbonnel, B., Cherney, D.Z.I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., Gantz, I., Terra, S.G., Masiukiewicz, U., Cannon, C.P.: Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA Cardiol.* 6, 148–158 (2021). <https://doi.org/10.1001/jamacardio.2020.4511>
14. Abdul-Ghani, M., Del Prato, S., Chilton, R., DeFronzo, R.A.: SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. *Diabetes Care.* 39, 717–725 (2016). <https://doi.org/10.2337/dc16-0041>
15. Said, S., Hernandez, G.T.: The link between chronic kidney disease and cardiovascular disease. *J Nephropathol.* 3, 99–104 (2014). <https://doi.org/10.12860/jnp.2014.19>
16. Engelhardt, K., Ferguson, M., Rosselli, J.L.: Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors. *Ann Pharmacother.* 55, 543–548 (2021). <https://doi.org/10.1177/1060028020951928>
17. Sridharan, K., Sivaramakrishnan, G.: Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression. *J Clin Med.* 13, 1748 (2024). <https://doi.org/10.3390/jcm13061748>
18. Sharma, A.: Tracing of Alpha-to-Beta Cell Transition Following Treatment with CHIR-Injected Human Multipotent Stromal Cell Secreted Proteins, <https://hdl.handle.net/20.500.14721/39609>, (2026)
19. Haider, S.H., Irfan, A., Sheikh, S.M., Larik, M.O., Raza, A., Khabir, Y.: Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients. *Clin Med Insights Cardiol.* 19, 11795468251347777 (2025). <https://doi.org/10.1177/11795468251347777>
20. O'Neill, D.E., Forman, D.E.: Cardiovascular care of older adults. *BMJ.* 374, n1593 (2021). <https://doi.org/10.1136/bmj.n1593>

CITE AS: Waiswa Arajab (2026). Precision SGLT2 Inhibitor Strategies for Cardiovascular and Renal Outcomes in Type 2 Diabetes. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 100-104. <https://doi.org/10.59298/IDOSR/JES/06/122100104>